| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/HMG/DDS379 |
| P8608 | Fatcat ID | release_4qapryzjgvd47lew2k25qvehku |
| P932 | PMC publication ID | 3510756 |
| P698 | PubMed publication ID | 22965876 |
| P5875 | ResearchGate publication ID | 230830413 |
| P50 | author | Haiqun Jia | Q79507704 |
| P2093 | author name string | Elizabeth A Thomas | |
| Joan S Steffan | |||
| Ryan J Kast | |||
| P2860 | cites work | Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme | Q24311567 |
| SUMO modification of Huntingtin and Huntington's disease pathology | Q24324137 | ||
| The IKK complex contributes to the induction of autophagy | Q24329117 | ||
| Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia | Q24600027 | ||
| The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice | Q24656405 | ||
| The roles of intracellular protein-degradation pathways in neurodegeneration | Q28269322 | ||
| Impairment of the ubiquitin-proteasome system by protein aggregation | Q29614556 | ||
| Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila | Q29616737 | ||
| IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. | Q30435758 | ||
| ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease | Q30478632 | ||
| Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice | Q30506469 | ||
| Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy | Q31832226 | ||
| Apoptotic and autophagic cell death induced by histone deacetylase inhibitors | Q33583208 | ||
| Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice | Q33594383 | ||
| Transcriptional dysregulation in Huntington's disease | Q34001953 | ||
| Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases | Q34580240 | ||
| Does Huntingtin play a role in selective macroautophagy? | Q34618914 | ||
| Histone deacetylase inhibitors: possible implications for neurodegenerative disorders | Q34743081 | ||
| Transcriptional abnormalities in Huntington disease | Q35113363 | ||
| Polyglutamine diseases: a transcription disorder? | Q35207444 | ||
| Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death | Q35922012 | ||
| Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. | Q36482299 | ||
| Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice | Q36534628 | ||
| Striatal specificity of gene expression dysregulation in Huntington's disease | Q36597436 | ||
| Sex-dependent effect of BAG1 in ameliorating motor deficits of Huntington disease transgenic mice | Q36701847 | ||
| Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease | Q36959352 | ||
| Therapeutic application of histone deacetylase inhibitors for central nervous system disorders | Q37283454 | ||
| Isoform-specific histone deacetylase inhibitors: the next step? | Q37415758 | ||
| Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity | Q37447680 | ||
| Targets and consequences of protein SUMOylation in neurons. | Q37728628 | ||
| Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. | Q40111505 | ||
| Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. | Q40241487 | ||
| Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. | Q40467483 | ||
| Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. | Q40515168 | ||
| Acetylation targets mutant huntingtin to autophagosomes for degradation | Q41773329 | ||
| Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases | Q42109512 | ||
| In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets | Q42488533 | ||
| The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. | Q44025697 | ||
| Neurodegeneration. A glutamine-rich trail leads to transcription factors | Q44037179 | ||
| Cognitive Enhancing Properties and Tolerability of Cholinergic Agents in Mice: A Comparative Study of Nicotine, Donepezil, and SIB-1553A, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors | Q44407158 | ||
| Neuronal induction of the immunoproteasome in Huntington's disease. | Q44699105 | ||
| Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases | Q45293883 | ||
| Modulation of nucleosome dynamics in Huntington's disease | Q45304739 | ||
| Global changes to the ubiquitin system in Huntington's disease. | Q45305824 | ||
| T-maze alternation in the rodent | Q48218933 | ||
| The ubiquitin-proteasome pathway in Huntington's disease. | Q55433686 | ||
| Selective autophagy: ubiquitin-mediated recognition and beyond | Q84974064 | ||
| P433 | issue | 24 | |
| P921 | main subject | Huntington's disease | Q190564 |
| autophagy | Q288322 | ||
| P304 | page(s) | 5280-5293 | |
| P577 | publication date | 2012-09-10 | |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems | |
| P478 | volume | 21 |
| Q33920945 | A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice |
| Q28084605 | Autophagy in neurodegenerative diseases: from mechanism to therapeutic approach |
| Q34353711 | Class I HDAC imaging using [ (3)H]CI-994 autoradiography |
| Q37611722 | Contribution of Neuroepigenetics to Huntington's Disease. |
| Q36892975 | DNA methylation in Huntington's disease: Implications for transgenerational effects |
| Q35152946 | Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies |
| Q91788987 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors |
| Q35403365 | Differential effect of HDAC3 on cytoplasmic and nuclear huntingtin aggregates. |
| Q35782283 | Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease |
| Q28073686 | Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases |
| Q28486205 | Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington's Disease |
| Q41209870 | EpiDBase: a manually curated database for small molecule modulators of epigenetic landscape |
| Q89050478 | Epigenetic Regulation in Neurodegenerative Diseases |
| Q28297936 | Epigenetic mechanisms of neurodegeneration in Huntington's disease |
| Q53428761 | GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. |
| Q34926539 | HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation |
| Q34218076 | HDAC3 controls gap 2/mitosis progression in adult neural stem/progenitor cells by regulating CDK1 levels |
| Q47984258 | Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development |
| Q100378830 | Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease mice |
| Q38215303 | Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors |
| Q38085375 | Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. |
| Q35149824 | Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich's Ataxia. |
| Q64969037 | Mechanisms of protein toxicity in neurodegenerative diseases. |
| Q47280331 | Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease |
| Q35960375 | Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue. |
| Q39241744 | Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases. |
| Q36763900 | Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT. |
| Q34488569 | Quantitative proteomic analysis identifies targets and pathways of a 2-aminobenzamide HDAC inhibitor in Friedreich's ataxia patient iPSC-derived neural stem cells. |
| Q92932473 | Recent progress in the role of autophagy in neurological diseases |
| Q64075700 | Reducing gene dosage induces dopaminergic neuronal loss and motor impairments in knockout mice |
| Q27306293 | Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes |
| Q48771662 | Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington's disease. |
| Q37596830 | SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation |
| Q54965947 | Salivary levels of total huntingtin are elevated in Huntington's disease patients. |
| Q38211724 | Stem cell therapy and cellular engineering for treatment of neuronal dysfunction in Huntington's disease |
| Q55284103 | Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models. |
| Q38361065 | Targeting histone deacetylases: a novel approach in Parkinson's disease |
| Q35975087 | The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice |
| Q57896358 | The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease |
| Q49717083 | The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay. |
| Q38527233 | The epigenetics of aging and neurodegeneration. |
| Q33784471 | The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1 |
| Q89771533 | The impact of proteostasis dysfunction secondary to environmental and genetic causes on neurodegenerative diseases progression and potential therapeutic intervention |
| Q26823365 | The many faces of autophagy dysfunction in Huntington's disease: from mechanism to therapy |
| Q38234971 | The potential of epigenetic therapies in neurodegenerative diseases |
| Q28087539 | The promise and perils of HDAC inhibitors in neurodegeneration |
| Q29614834 | The role of autophagy in neurodegenerative disease |
| Q36501584 | The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models |
| Q34487604 | Therapeutic advances in Huntington's Disease |
| Q53716390 | Therapy development in Huntington disease: From current strategies to emerging opportunities. |
| Q38234883 | Ubiquitin pathways in neurodegenerative disease |
Search more.